Predict your next investment

Corporation
HEALTHCARE | Biotechnology
biolifesolutions.com

See what CB Insights has to offer

Founded Year

1987

Stage

PIPE | IPO

Market Cap

1.35B

Stock Price

40.93

Revenue

$0000 

About BioLife Solutions

BioLife Solutions (NASDAQ: BLFS) provides biopreservation tools for cells, tissues, and organs that aims to facilitate basic and applied research and the commercialization of new therapies by maintaining the health and function of biologic source material and finished products during manufacturing, distribution, and clinical administration.

BioLife Solutions Headquarter Location

3303 Monte Villa Parkway Suite 310

Bothell, Washington, 98021,

United States

866-424-6543

Latest BioLife Solutions News

08:00 ET BioLife Solutions Leverages Expanded Bioproduction Tools and Services Portfolio in Multipoint Engagement with Leading C...

Oct 4, 2021

CryoStor® Freezer Media, evo® Smart Shipper and SciSafe® Storage Services All Utilized to Support Potential Q4 US Regulatory Approval and 2022 Commercial Launch News provided by Share this article Share this article BOTHELL, Wash., Oct. 4, 2021 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS ) a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced a broad engagement with a leading cell therapy developer, wherein BioLife's CryoStor freeze media, evo cold chain management platform and SciSafe storage services with Stirling UltraCold freezers are all being utilized by this top 10 largest global pharmaceutical company to support the anticipated regulatory approval and commercial launch of a new CAR T-cell therapy. CryoStor CS 10 SciSafe Mike Rice, BioLife's Chairman and CEO, commented, "This is another relevant example of how we are leveraging our relationships with cell and gene therapy companies to expand our engagements by providing multiple bioproduction tools and services used in manufacturing, storage and distribution. Our class-defining CryoStor biopreservation media and evo cold chain management platform, and state-of-the-art and secure biostorage services and facilities enable research teams to focus on what matters most to them – to improve the lives of patients through the discovery, manufacturing and commercialization of biologic medicines that can prevent, treat, and cure some of the world's most life-threatening diseases." To date, BioLife's CryoStor freeze media is exclusively used in the manufacturing process of every dose of the following approved biologic therapies. YESCARTA® from Kite, a GILEAD company, approved in the USA, EU, Japan, and China ZYNTEGLO™ from bluebird bio, approved in the EU BREYANZI® from Bristol Myers Squibb, approved in the USA and Japan TECARTUS® from Kite/Gilead, approved in the USA SKYSONA™ from bluebird bio, approved in the EU ABECMA® from Bristol Myers Squib and bluebird bio, approved in the USA, EU, and Canada Undisclosed – approved outside the USA CryoStor is also exclusively embedded in the manufacturing and the final drug formulation of 3 additional cell therapies that could receive regulatory approval in the next 3-4 quarters. About BioLife Solutions BioLife Solutions is a leading supplier of cell and gene therapy bioproduction products and services. Our portfolio includes our proprietary CryoStor® freeze media and HypoThermosol® shipping and storage media, ThawSTAR® family of automated, water-free thawing products, evo® cold chain management system, Custom Biogenic Systems® high-capacity cryogenic freezers, Stirling Ultracold ULT freezers, SciSafe biologic materials storage, and Sexton cell processing tools. For more information, please visit www.biolifesolutions.com , www.scisafe.com , www.stirlingultracold.com , and www.sextonbio.com , and follow BioLife on Twitter . Cautions Regarding Forward Looking Statements Except for historical information contained herein, this press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements concerning the company's ability to implement its business strategy and anticipated business and operations, the potential utility of and market for the company's products and services and the company's ability to cross sell its products and services, including its recently acquired products, potential market expansion, including with consideration to our recent acquisitions and giving effect to the COVID-19 pandemic, regulatory approvals and/or commercial manufacturing of our customers' products, potential customer revenue, and our ability to retain our current customers on an exclusive basis, if at all. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, market adoption of the company's products (including the company's recently acquired products), the ability of the company to continue to implement its business strategy, market volatility, competition, litigation, the impact of the COVID-19 pandemic, and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law. Contacts:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing BioLife Solutions

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

BioLife Solutions is included in 1 Expert Collection, including Deloitte 2019 Technology Fast500 - North America.

D

Deloitte 2019 Technology Fast500 - North America

501 items

BioLife Solutions Patents

BioLife Solutions has filed 20 patents.

The 3 most popular patent topics include:

  • Apple cultivars
  • Cooling technology
  • Biotechnology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/23/2017

2/9/2021

Thermodynamics, Sensors, Phase transitions, Cooling technology, Cell biology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

5/23/2017

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

2/9/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Thermodynamics, Sensors, Phase transitions, Cooling technology, Cell biology

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

BioLife Solutions Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

BioLife Solutions Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.